AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMUGENE LTD

0.070

-0.001-1.41%

Volume:1.46M

Turnover:103.23K

Market Cap:36.21M

PE:-0.31

High:0.073

Open:0.071

Low:0.070

Close:0.071

52wk High:0.460

52wk Low:0.068

Shares:517.30M

Float Shares:254.20M

Volume Ratio:0.51

T/O Rate:0.57%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.225

EPS(LYR):-0.316

ROE:-389.83%

ROA:-123.93%

PB:4.02

PE(LYR):-0.22

Loading ...

Overview Company News Filings

Imugene Ltd Says Leslie Chong Resigns as CEO

Imugene - Leslie Chong Resigns as CEO of Imugene

THOMSON REUTERS

Imugene Ltd-ceo Resignation

THOMSON REUTERS

Australia's Imugene Loses Most in over 8-years on Discounted Placement

Imugene to Raise A$11.12 Million Via Placement at A$0.095 Per Share

Imugene - to Raise A$11.12 Mln Via Placement at A$0.095 Per Share

THOMSON REUTERS

Imugene - Requests Trading Halt Pending Proposed Capital Raising Announcement

THOMSON REUTERS

Imugene Says Additional Patient in BTKi Group of Azer-Cel Phase 1b Study Achieves Complete Response, Shares Surge 26%

MT Newswires Live

BUZZ-Australia's Imugene surges after US FDA grants product Fast Track status

Imugene - FDA Grants Fast Track Designation to Imugene's Azer-Cel for Cll/Sll and Mzl

THOMSON REUTERS

Imugene Ltd-Azer-Cel Granted FDA Fast Track Designation for Cll and Mzl

THOMSON REUTERS

Imugene Ltd-Appointment of 2 Non-Executive Directors

THOMSON REUTERS

Imugene Reports 81% Overall Response Rate in Azer-Cel Phase 1b Study, Shares Surge 22%

MT Newswires Live

Imugene Ltd-Egm Results and Share Purchase Plan Final Allotment

THOMSON REUTERS

BUZZ-Precision Bio rises after quarterly results beat estimates

BRIEF-Imugene Launches A$12 Mln Placement At A$0.18 Per Share

Imugene Ltd - a$12 Mln Placement at a$0.18 per Share

THOMSON REUTERS

BRIEF-Imugene Seeks Trading Halt Pending Proposed Capital Raising Announcement

BRIEF-Imugene Posts HY Net Loss Attributable A$37.8 Million

Imugene Ltd - Hy Net Loss Attributable a$37.8 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/IMU.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","market":"AU","secType":"STK","nameCN":"IMUGENE LTD","latestPrice":0.07,"timestamp":1787897520000,"preClose":0.071,"halted":0,"volume":1459276,"delay":0,"changeRate":-0.01408450704225334,"nameEN":"IMUGENE LTD","floatShares":254199099,"shares":517298800,"eps":-0.225,"marketStatus":"Not Yet Opened","change":-0.001,"latestTime":"08-28 16:12:00 AEST","open":0.071,"high":0.073,"low":0.07,"amount":103225,"amplitude":0.042254,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.225,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788134400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.071,"openAndCloseTimeList":[[1787875200000,1787896800000]],"volumeRatio":0.5055595839536922,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMU.AU","preClose":0.07,"auctionPrice":0.071,"auctionVolume":8477,"auctionTime":1788123803351,"referenceTime":1787913003093,"auction":1,"marketStatus":"盘前竞价","timestamp":1788123803351}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","floatShares":254199099,"roa":"-123.93%","roe":"-389.83%","lyrEps":-0.315594,"volumeRatio":0.5055595839536922,"shares":517298800,"dividePrice":0,"high":0.073,"amplitude":0.042254,"preClose":0.071,"low":0.07,"week52Low":0.068,"pbRate":"4.02","psRate":"21.05","week52High":0.46,"institutionHeld":0,"latestPrice":0.07,"eps":-0.225,"divideRate":0,"volume":1459276,"delay":0,"ttmEps":-0.225,"open":0.071,"prevYearClose":0.365,"prevWeekClose":0.07,"prevMonthClose":0.085,"prevQuarterClose":0.115,"fiveDayClose":0.082,"twentyDayClose":0.085,"sixtyDayClose":0.093},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMU.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-07-02","symbol":"IMU.AU","type":"split","dateTimestamp":1751378400000,"forFactor":34,"toFactor":1,"ratio":34}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMU.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2654093770","title":"Imugene Ltd Says Leslie Chong Resigns as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2654093770","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654093770?lang=en_us&edition=fundamental","pubTime":"2026-07-27 09:53","pubTimestamp":1785117224,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Ltd Says Leslie Chong Resigns As CEOJuly 27 (Reuters)-Imugene LtdIMU.AX:CEO RESIGNATIONLESLIE CHONG RESIGNS AS CEO OF IMUGENELESLIE CHONG STEPS DOWN AS MANAGING DIRECTOR AND CEO FOR PERSONAL REASONSFurther company coverage:IMU.AX","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUE1D4RX7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654558060","title":"Imugene - Leslie Chong Resigns as CEO of Imugene","url":"https://stock-news.laohu8.com/highlight/detail?id=2654558060","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654558060?lang=en_us&edition=fundamental","pubTime":"2026-07-27 07:39","pubTimestamp":1785109176,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260726:nTUE1D4RX7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMU.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654060530","title":"Imugene Ltd-ceo Resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2654060530","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654060530?lang=en_us&edition=fundamental","pubTime":"2026-07-27 07:39","pubTimestamp":1785109176,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260726:nTUE1D4RX7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMU.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649605741","title":"Australia's Imugene Loses Most in over 8-years on Discounted Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2649605741","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649605741?lang=en_us&edition=fundamental","pubTime":"2026-07-07 11:43","pubTimestamp":1783395831,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Imugene loses most in over 8-years on discounted placement** Shares of Australia's ImugeneIMU.AXfalls 22.2% to A$0.105, heading for its biggest pct loss since mid-November, 2017** Cell therapy coreceivesfirm commitments to raise about A$11.12 million  via share placement** Placement involves issue of 117.1 million shares at A$0.095 per share** Placement at a discount of 29.6% to co's last close** Funds will be used advance production of co's cellular cancer therapy drug, azer-cel, following positive clinical data** Near 8.4 million shares change hands; 2.1x the 30 day average** Stock down 71.9% YTD, including day's moves","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4N439093:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649608210","title":"Imugene to Raise A$11.12 Million Via Placement at A$0.095 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2649608210","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649608210?lang=en_us&edition=fundamental","pubTime":"2026-07-07 09:45","pubTimestamp":1783388733,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene To Raise A$11.12 Million Via Placement At A$0.095 Per ShareJuly 7 (Reuters)-Imugene LtdIMU.AX:TO RAISE A$11.12 MILLION VIA PLACEMENT AT A$0.095 PER SHAREFurther company coverage:IMU.AX","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nFWN4380XS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649672053","title":"Imugene - to Raise A$11.12 Mln Via Placement at A$0.095 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2649672053","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649672053?lang=en_us&edition=fundamental","pubTime":"2026-07-07 07:50","pubTimestamp":1783381808,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nFWN4380XS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMU.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648263976","title":"Imugene - Requests Trading Halt Pending Proposed Capital Raising Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2648263976","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648263976?lang=en_us&edition=fundamental","pubTime":"2026-07-03 07:31","pubTimestamp":1783035104,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nFWN4340VP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648594066","title":"Imugene Says Additional Patient in BTKi Group of Azer-Cel Phase 1b Study Achieves Complete Response, Shares Surge 26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648594066","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648594066?lang=en_us&edition=fundamental","pubTime":"2026-07-01 12:48","pubTimestamp":1782881297,"startTime":"0","endTime":"0","summary":"Imugene  said additional patient data from the concurrent Bruton's tyrosine-protein inhibitor  group of its azer-cel therapy candidate phase 1b study showed a complete response, according to a Friday Australian bourse filing.Azer-cel is an off-the-shelf allogeneic CAR T cell therapy targeting the CD19 protein to treat blood cancers.The mantle cell lymphoma  patient was the first one treated in the study and had previously failed BTKi therapy. The patient achieved a complete response at the day 28 assessment.To date, four patients have been dosed in the concurrent BTKi group, and two of these patients are evaluable, both achieving a complete response.Its shares surged 26% in recent trading on Wednesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","MCL.AU","BK7137","IMU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642512914","title":"BUZZ-Australia's Imugene surges after US FDA grants product Fast Track status","url":"https://stock-news.laohu8.com/highlight/detail?id=2642512914","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642512914?lang=en_us&edition=fundamental","pubTime":"2026-06-09 13:23","pubTimestamp":1780982620,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Imugene surges after US FDA grants product Fast Track status** Shares of Imugene IMU.AX rise as much as 14.1% to A$0.105, their biggest intraday pct gain since May 26** Cell therapy co says U.S. Food and Drug Administration grants Fast Track Designation to azer-cel ** Fast Track Designation for two indications: relapsed or refractory Chronic Lymphocytic Leukaemia/ Small Lymphocytic Lymphoma  and relapsed or refractory Marginal Zone Lymphoma ** Azer-cel an off-the-shelf, CD19-directed CAR T-cell therapy engineered to overcome logistical constraints of autologous CAR T therapies, co says** YTD, IMU shares down 74.3%  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nL4N42H0CZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642589074","title":"Imugene - FDA Grants Fast Track Designation to Imugene's Azer-Cel for Cll/Sll and Mzl","url":"https://stock-news.laohu8.com/highlight/detail?id=2642589074","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642589074?lang=en_us&edition=fundamental","pubTime":"2026-06-09 08:50","pubTimestamp":1780966213,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nTUE9H942V:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642188458","title":"Imugene Ltd-Azer-Cel Granted FDA Fast Track Designation for Cll and Mzl","url":"https://stock-news.laohu8.com/highlight/detail?id=2642188458","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642188458?lang=en_us&edition=fundamental","pubTime":"2026-06-09 08:50","pubTimestamp":1780966213,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nTUE9H942V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638256396","title":"Imugene Ltd-Appointment of 2 Non-Executive Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2638256396","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638256396?lang=en_us&edition=fundamental","pubTime":"2026-05-26 07:47","pubTimestamp":1779752871,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260525:nTUEBYJXBY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMU.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637645073","title":"Imugene  Reports 81% Overall Response Rate in Azer-Cel Phase 1b Study, Shares Surge 22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637645073","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637645073?lang=en_us&edition=fundamental","pubTime":"2026-05-22 10:35","pubTimestamp":1779417331,"startTime":"0","endTime":"0","summary":"Imugene  said data from its azer-cel Phase 1b abstract, published on the American Society of Clinical Oncology  website, showed an overall response rate  of 81% among 16 evaluable patients, according to a Friday Australian bourse filing.The company said Azer-cel, an off-the-shelf allogeneic CAR T cell therapy targeting CD19 to treat blood cancers, showed responses across multiple lymphoma and leukemia subtypes, including a 60% response rate in diffuse large B-cell lymphoma  and a 100% response rate in marginal zone lymphoma .The company's shares rose 22% in recent Friday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ORR","IMU.AU","BK7067","BK7095","BK7508","ORR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629199008","title":"Imugene Ltd-Egm Results and Share Purchase Plan Final Allotment","url":"https://stock-news.laohu8.com/highlight/detail?id=2629199008","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629199008?lang=en_us&edition=fundamental","pubTime":"2026-04-23 10:33","pubTimestamp":1776911582,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nTUE1YF4YR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618831132","title":"BUZZ-Precision Bio rises after quarterly results beat estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2618831132","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618831132?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:37","pubTimestamp":1773319051,"startTime":"0","endTime":"0","summary":"BUZZ-Precision Bio rises after quarterly results beat estimates** Shares of biotech firm Precision BioSciences DTIL.O rise 8.89% to $5.51 premarket ** Co posts Q4 profit of $1.05 per share, while analysts were expecting a loss of 54 cents per share, according to data compiled by LSEG** Posts Q4 revenue of $34.2 million, beating analysts' estimate of $9.1 million** Says revenue increase was driven mainly by $26.2 million booked under its Novartis collaboration deal and $8 million from the Imugene license agreement** DTIL shares rose over 9% in 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nL4N40018N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMU.AU","BK7508","DTIL","BK4139","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618143249","title":"BRIEF-Imugene Launches A$12 Mln Placement At A$0.18 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2618143249","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618143249?lang=en_us&edition=fundamental","pubTime":"2026-03-11 16:05","pubTimestamp":1773216351,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Launches A$12 Mln Placement At A$0.18 Per ShareMarch 11 (Reuters) - Imugene Ltd IMU.AX:A$12 MILLION PLACEMENT AT A$0.18 PER SHARETO RAISE UP TO A$20 MILLION VIA PLACEMENT AND SPP AT A$0.18 PER SHAREFurther company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nFWN3ZY1GM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMU.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618899134","title":"Imugene Ltd - a$12 Mln Placement at a$0.18 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2618899134","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618899134?lang=en_us&edition=fundamental","pubTime":"2026-03-11 10:36","pubTimestamp":1773196580,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nFWN3ZY1GM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618493670","title":"BRIEF-Imugene Seeks Trading Halt Pending Proposed Capital Raising Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2618493670","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618493670?lang=en_us&edition=fundamental","pubTime":"2026-03-10 06:13","pubTimestamp":1773094435,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Seeks Trading Halt Pending Proposed Capital Raising AnnouncementMarch 10 (Reuters) - Imugene Ltd IMU.AX:SEEKS TRADING HALT PENDING PROPOSED CAPITAL RAISING ANNOUNCEMENTFurther company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX0WK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614720448","title":"BRIEF-Imugene Posts HY Net Loss Attributable A$37.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614720448","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614720448?lang=en_us&edition=fundamental","pubTime":"2026-02-25 09:38","pubTimestamp":1771983489,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Posts HY Net Loss Attributable A$37.8 MillionFeb 25 (Reuters) - Imugene Ltd IMU.AX:HY NET LOSS ATTRIBUTABLE A$37.8 MILLIONFurther company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZK1AG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMU.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614204147","title":"Imugene Ltd - Hy Net Loss Attributable a$37.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614204147","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614204147?lang=en_us&edition=fundamental","pubTime":"2026-02-25 09:37","pubTimestamp":1771983472,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZK1AG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMU.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}]}}